Search

Displaying results 1321 - 1330 of 1994 in total
  1. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.

  2. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    While about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower … In a large, randomized, open-label, multicenter, phase III trial, the treatment of mifamurtide in conjunction with three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate

  3. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 ...

  4. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and

  5. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent in...

  6. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm c...

  7. Drug

    Lansoprazole

    go.drugbank.com/drugs/DB00448
    ApprovedInvestigational

    Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective...

    Mixtures: HELIPAK 500 + 30 + 1000mg TEDAVİ PAKETİ, 7 TABLET, HELIPAK 500 + 30 + 1000mg TEDAVİ PAKETİ, 14 TABLETProducts: Heartburn Relief 24 hour, Lansoprazole Heartburn Relief 24 Hour
  8. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation. It reduces symptoms in patients with pulmonary arteri...

  9. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury.

  10. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.